These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26440969)

  • 1. Serial investigation of PTPN11 mutation in nonhematopoietic tissues in a patient with juvenile myelomonocytic leukemia who was treated with unrelated cord blood transplantation.
    Hiramoto R; Imamura T; Muramatsu H; Wang X; Kanayama T; Zuiki M; Yoshida H; Moroto M; Fujiki A; Chiyonobu T; Osone S; Ishida H; Kojima S; Hosoi H
    Int J Hematol; 2015 Dec; 102(6):719-22. PubMed ID: 26440969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia.
    Doisaki S; Muramatsu H; Shimada A; Takahashi Y; Mori-Ezaki M; Sato M; Kawaguchi H; Kinoshita A; Sotomatsu M; Hayashi Y; Furukawa-Hibi Y; Yamada K; Hoshino H; Kiyoi H; Yoshida N; Sakaguchi H; Narita A; Wang X; Ismael O; Xu Y; Nishio N; Tanaka M; Hama A; Koike K; Kojima S
    Blood; 2012 Aug; 120(7):1485-8. PubMed ID: 22753870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl.
    Jakovljević G; Kardum-Skelin I; Rogosić S; Nakić M
    Coll Antropol; 2010 Mar; 34(1):251-4. PubMed ID: 20432758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
    Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK
    J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center.
    Miao Y; Li B; Ding L; Zhu H; Luo C; Wang J; Luo C; Chen J
    Eur J Pediatr; 2020 Mar; 179(3):463-472. PubMed ID: 31807902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
    Mulero-Navarro S; Sevilla A; Roman AC; Lee DF; D'Souza SL; Pardo S; Riess I; Su J; Cohen N; Schaniel C; Rodriguez NA; Baccarini A; Brown BD; Cavé H; Caye A; Strullu M; Yalcin S; Park CY; Dhandapany PS; Yongchao G; Edelmann L; Bahieg S; Raynal P; Flex E; Tartaglia M; Moore KA; Lemischka IR; Gelb BD
    Cell Rep; 2015 Oct; 13(3):504-515. PubMed ID: 26456833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.
    Gandre-Babbe S; Paluru P; Aribeana C; Chou ST; Bresolin S; Lu L; Sullivan SK; Tasian SK; Weng J; Favre H; Choi JK; French DL; Loh ML; Weiss MJ
    Blood; 2013 Jun; 121(24):4925-9. PubMed ID: 23620576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
    Dong L; Yu WM; Zheng H; Loh ML; Bunting ST; Pauly M; Huang G; Zhou M; Broxmeyer HE; Scadden DT; Qu CK
    Nature; 2016 Nov; 539(7628):304-308. PubMed ID: 27783593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete Resolution of Lymphoid Interstitial Pneumonia in a Patient With Juvenile Myelomonocytic Leukemia Treated With Allogeneic Bone Marrow Transplant: Killing 2 Birds With 1 Stone.
    Vatsayan A; Talati R; Nagle K; Cabral L; Cammock S; Dimarino A; Egler R; Saab S; Dalal J
    J Pediatr Hematol Oncol; 2018 Jul; 40(5):e315-e318. PubMed ID: 29023302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
    Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
    Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia.
    Unal S; Cetin M; Kutlay NY; Elmas SA; Gumruk F; Tukun A; Tuncer M; Gurgey A
    Ann Hematol; 2010 Apr; 89(4):359-64. PubMed ID: 19798502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.
    Shigemura T; Matsuda K; Kurata T; Sakashita K; Okuno Y; Muramatsu H; Yue F; Ebihara Y; Tsuji K; Sasaki K; Nakahata T; Nakazawa Y; Koike K
    Br J Haematol; 2019 Oct; 187(2):163-173. PubMed ID: 31222725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonsyndromic Juvenile Myelomonocytic Leukemia With PTPN11 Mutation in a 9-Year-old Girl.
    Sarper N; Gelen SA; Zengin E; Demirsoy U; Erçin C
    J Pediatr Hematol Oncol; 2015 Aug; 37(6):486-7. PubMed ID: 26181421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of Gene Mutation and Clinical Characteristics in 19 Children with Juvenile Myelomonocytic Leukemia].
    Weng KZ; Zheng YZ; Zhuang SQ; Chen HY; LE SH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1811-1818. PubMed ID: 33283703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.
    Tasian SK; Casas JA; Posocco D; Gandre-Babbe S; Gagne AL; Liang G; Loh ML; Weiss MJ; French DL; Chou ST
    Leukemia; 2019 Jan; 33(1):181-190. PubMed ID: 29884903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft versus leukemia effect against juvenile myelomonocytic leukemia after unrelated cord blood transplantation.
    Tanoshima R; Goto H; Yanagimachi M; Kajiwara R; Kuroki F; Yokota S
    Pediatr Blood Cancer; 2008 Mar; 50(3):665-7. PubMed ID: 17437289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
    Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC
    Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Juvenile myelomonocytic leukaemia presentation after preceding juvenile xanthogranuloma harbouring an identical somatic PTPN11 mutation.
    Bátai B; Krizsán S; Gángó A; Hegyi L; Csóka M; Erdélyi DJ; Csomor J; Kállay K; Bödör C
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28368. PubMed ID: 32558336
    [No Abstract]   [Full Text] [Related]  

  • 19. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.
    Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical features and prognosis of juvenile myelomonocytic leukemia: an analysis of 63 cases].
    Yang WY; Liu LP; Liu F; Qi BQ; Chang LX; Zhang L; Chen XJ; Zou Y; Chen YM; Guo Y; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Mar; 25(3):265-271. PubMed ID: 36946161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.